Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582381518> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2582381518 endingPage "5279" @default.
- W2582381518 startingPage "5279" @default.
- W2582381518 abstract "Abstract Background: Aspergillosis is a lethal infection of immunocompromised patients that respond poorly to antifungal therapy. Caspofungin (CAS) or Posaconazole (POS) as salvage monotherapy for IA have response rates of 45% and 42% respectively. Preliminary results of in vitro studies, animal models and clinical studies suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species. Methods: Seven adult patients after unrelated haematopoietic stem cell transplantation, with proven, probable or possible IA (per EORTC/MSG criteria) and refractory to standard antifungal therapy received Caspofungin plus Posaconazole (standard monotherapy dosage). All patients had > 3 days of combination antifungal therapy. Underlying diseases were AML (n=5), Biphenotypic leukaemia (n=1), Mantle cell Lymphoma (n=1). Three patients were neutropenic (ANC<500), all patients received immunosuppressive medication. IA sites were lung (n=6) and liver (n=1). All patients were evaluable for toxicity. Efficacy was assessed by signs, symptoms and CT-scan/ultrasound. Favourable responses (complete or partial) required significant clinical and radiographic/ultrasound improvement. Results: Success at end of combination therapy (EOCT) was seen in six patients (86%). One critically ill patient died (due to bacterial sepsis and severe acute GvHD) four days after first administration of combination therapy. One patient with complete radiographic response died 20 days after EOCT due to bacterial sepsis in relapse of AML. Combination therapy at 4 to 59 (mean 35.7) days was well tolerated. No patient discontinued combination therapy due to toxicity. Follow up from start of combination therapy was 4 to 204 (mean 79.8) days. Conclusion: Randomized trials are warranted to determine whether this combination should be used as primary therapy for aspergillosis." @default.
- W2582381518 created "2017-02-03" @default.
- W2582381518 creator A5004517634 @default.
- W2582381518 creator A5053564273 @default.
- W2582381518 creator A5060553394 @default.
- W2582381518 creator A5060690263 @default.
- W2582381518 creator A5063350015 @default.
- W2582381518 creator A5064865713 @default.
- W2582381518 creator A5067173808 @default.
- W2582381518 creator A5070188546 @default.
- W2582381518 creator A5071316542 @default.
- W2582381518 date "2006-11-16" @default.
- W2582381518 modified "2023-10-01" @default.
- W2582381518 title "Experiences with Caspofungin Plus Posaconazole in Immunocompromised Adults with Invasive Aspergillosis (IA) Refractory to Prior Standard Therapy." @default.
- W2582381518 doi "https://doi.org/10.1182/blood.v108.11.5279.5279" @default.
- W2582381518 hasPublicationYear "2006" @default.
- W2582381518 type Work @default.
- W2582381518 sameAs 2582381518 @default.
- W2582381518 citedByCount "0" @default.
- W2582381518 crossrefType "journal-article" @default.
- W2582381518 hasAuthorship W2582381518A5004517634 @default.
- W2582381518 hasAuthorship W2582381518A5053564273 @default.
- W2582381518 hasAuthorship W2582381518A5060553394 @default.
- W2582381518 hasAuthorship W2582381518A5060690263 @default.
- W2582381518 hasAuthorship W2582381518A5063350015 @default.
- W2582381518 hasAuthorship W2582381518A5064865713 @default.
- W2582381518 hasAuthorship W2582381518A5067173808 @default.
- W2582381518 hasAuthorship W2582381518A5070188546 @default.
- W2582381518 hasAuthorship W2582381518A5071316542 @default.
- W2582381518 hasConcept C126322002 @default.
- W2582381518 hasConcept C141071460 @default.
- W2582381518 hasConcept C142424586 @default.
- W2582381518 hasConcept C16005928 @default.
- W2582381518 hasConcept C203014093 @default.
- W2582381518 hasConcept C2776391196 @default.
- W2582381518 hasConcept C2776694085 @default.
- W2582381518 hasConcept C2776999253 @default.
- W2582381518 hasConcept C2777063308 @default.
- W2582381518 hasConcept C2777408962 @default.
- W2582381518 hasConcept C2778566413 @default.
- W2582381518 hasConcept C2779320740 @default.
- W2582381518 hasConcept C2779548794 @default.
- W2582381518 hasConcept C2780402444 @default.
- W2582381518 hasConcept C2780651595 @default.
- W2582381518 hasConcept C2780690907 @default.
- W2582381518 hasConcept C2780775027 @default.
- W2582381518 hasConcept C2911091166 @default.
- W2582381518 hasConcept C29730261 @default.
- W2582381518 hasConcept C71924100 @default.
- W2582381518 hasConcept C86803240 @default.
- W2582381518 hasConcept C87355193 @default.
- W2582381518 hasConcept C90924648 @default.
- W2582381518 hasConceptScore W2582381518C126322002 @default.
- W2582381518 hasConceptScore W2582381518C141071460 @default.
- W2582381518 hasConceptScore W2582381518C142424586 @default.
- W2582381518 hasConceptScore W2582381518C16005928 @default.
- W2582381518 hasConceptScore W2582381518C203014093 @default.
- W2582381518 hasConceptScore W2582381518C2776391196 @default.
- W2582381518 hasConceptScore W2582381518C2776694085 @default.
- W2582381518 hasConceptScore W2582381518C2776999253 @default.
- W2582381518 hasConceptScore W2582381518C2777063308 @default.
- W2582381518 hasConceptScore W2582381518C2777408962 @default.
- W2582381518 hasConceptScore W2582381518C2778566413 @default.
- W2582381518 hasConceptScore W2582381518C2779320740 @default.
- W2582381518 hasConceptScore W2582381518C2779548794 @default.
- W2582381518 hasConceptScore W2582381518C2780402444 @default.
- W2582381518 hasConceptScore W2582381518C2780651595 @default.
- W2582381518 hasConceptScore W2582381518C2780690907 @default.
- W2582381518 hasConceptScore W2582381518C2780775027 @default.
- W2582381518 hasConceptScore W2582381518C2911091166 @default.
- W2582381518 hasConceptScore W2582381518C29730261 @default.
- W2582381518 hasConceptScore W2582381518C71924100 @default.
- W2582381518 hasConceptScore W2582381518C86803240 @default.
- W2582381518 hasConceptScore W2582381518C87355193 @default.
- W2582381518 hasConceptScore W2582381518C90924648 @default.
- W2582381518 hasIssue "11" @default.
- W2582381518 hasLocation W25823815181 @default.
- W2582381518 hasOpenAccess W2582381518 @default.
- W2582381518 hasPrimaryLocation W25823815181 @default.
- W2582381518 hasRelatedWork W1910184092 @default.
- W2582381518 hasRelatedWork W1965072000 @default.
- W2582381518 hasRelatedWork W1975757319 @default.
- W2582381518 hasRelatedWork W1976034631 @default.
- W2582381518 hasRelatedWork W2037295280 @default.
- W2582381518 hasRelatedWork W2042535852 @default.
- W2582381518 hasRelatedWork W2072014763 @default.
- W2582381518 hasRelatedWork W2145458651 @default.
- W2582381518 hasRelatedWork W2582381518 @default.
- W2582381518 hasRelatedWork W2105724102 @default.
- W2582381518 hasVolume "108" @default.
- W2582381518 isParatext "false" @default.
- W2582381518 isRetracted "false" @default.
- W2582381518 magId "2582381518" @default.
- W2582381518 workType "article" @default.